- Home
- MTNB vs TCRT Comparison
MTNB vs TCRT Comparison
Compare MTNB & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | TCRT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.3M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MTNB | TCRT |
|---|---|---|
| Price | $0.28 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 578.3K | 12.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $1.67 |
| 52 Week High | $3.09 | $4.57 |
Technical Indicators
Market Signals| Indicator | MTNB | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 44.86 |
| Support Level | N/A | $1.95 |
| Resistance Level | $0.66 | $2.37 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.70 | 32.06 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.